• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Vericel Corporation

    5/8/25 4:06:50 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VCEL alert in real time by email
    S-8 1 tm2514102d2_s8.htm FORM S-8

     

    Registration No. 333-

    As filed with the Securities and Exchange Commission on May 8, 2025.

     

     

    UNITED STATES SECURITIES AND EXCHANGE
    COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

     

    Vericel Corporation

    (Exact name of registrant as specified in its charter)

     

    Michigan 94-3096597
    (State or other jurisdiction (I.R.S. employer identification no.)
    of incorporation or organization)  

     

    64 Sidney St.

    Cambridge, Massachusetts 02139
    (Address of principal executive offices) (Zip code)

     

    Vericel Corporation Amended and Restated 2022 Omnibus Incentive Plan

    (Full title of the plans)

     

    Dominick Colangelo
    President and Chief Executive Officer
    Vericel Corporation
    64 Sidney St.

    Cambridge, Massachusetts 02139
    (Name and address of agent for service)

     

    (617) 588-5555

    (Telephone Number, Including area code, of Agent for Service)

     

    Copy to:

     

    Keith M. Townsend

    Robert J. Leclerc

    King & Spalding LLP

    1180 Peachtree Street, N.E.

    Atlanta, Georgia 30309

    Tel: (404) 572-4600

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer x   Accelerated filer o
    Non-accelerated filer o   Smaller reporting company o
        Emerging growth company o

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. o

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (the “Registration Statement”) is filed by Vericel Corporation, a Michigan corporation (the “Company” or the “Registrant”) pursuant to General Instruction E to Form S-8. The contents of the Registration Statements on Form S-8 previously filed on December 6, 2004 (File No. 333-121006), February 12, 2007 (File No. 333-140624), December 18, 2009 (File No. 333-163832), June 7, 2011 (File No. 333-174758), March 18, 2013 (File No. 333-187346), June 29, 2015 (File No. 333-205338), May 5, 2017 (File No. 333-217741), May 1, 2019 (File No. 333-231163), August 6, 2020 (File No. 333-241700) and May 6, 2022 (File No. 333-264747), as amended, are incorporated by reference herein and made a part hereof, except as supplemented, amended or superseded by the information set forth below. This Registration Statement on Form S-8 is filed by the Company to register an additional 5,000,000 shares of the Company’s common stock, no par value (the “Common Stock”), which are reserved for issuance under the Vericel Corporation Amended and Restated 2022 Omnibus Incentive Plan (the “Amended and Restated 2022 Plan”). The reservation of such shares was approved by the Company’s shareholders on April 30, 2025, at the annual meeting of the Company’s shareholders.

     

     

     

     

    EXHIBIT INDEX

     

     4.1   Vericel Corporation Amended and Restated 2022 Omnibus Incentive Plan, attached as Appendix I to the Company’s Proxy Statement, filed on March 20, 2025, incorporated herein by reference (File No. 001.35280).
         
    5.1*   Opinion of Dykema Gossett PLLC.
       
    23.1*   Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.
         
    23.2*   Consent of Dykema Gossett PLLC (included in Exhibit 5.1 hereto).
         
    24.1*   Power of Attorney (included in signature pages to this Registration Statement).
         
    107*   Filing Fee Table

     

     

    * Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on May 8, 2025.

     

    VERICEL CORPORATION  
         
    By: /s/ Dominick Colangelo  
      Dominick Colangelo  
      President and Chief Executive Officer  

     

    POWER OF ATTORNEY

     

    We, the undersigned officers and directors of Vericel Corporation, hereby severally constitute and appoint Dominick Colangelo and Joseph Mara, and each of them singly, our true and lawful attorneys, with full power to sign for us in our names in the capacities indicated below, any amendments to this Registration Statement on Form S-8 (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, and generally to do all things in our names and on our behalf in our capacities as officers and directors to enable Vericel Corporation, to comply with the provisions of the Securities Act of 1933, as amended, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said Registration Statement and all amendments thereto.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities indicated on May 8, 2025.

     

    Signature   Title
         
    /s/ Dominick C. Colangelo   President and Chief Executive Officer, Director
    Dominick C. Colangelo   (Principal Executive Officer)
         
    /s/ Joseph A. Mara   Chief Financial Officer
    Joseph A. Mara   (Principal Financial Officer)
         
    /s/ Jonathan D. Siegal   Vice President and Corporate Controller
    Jonathan D. Siegal    (Principal Accounting Officer)
         
    /s/ Robert Zerbe, M.D.   Chairman of the Board of Directors
    Robert Zerbe, M.D.    
         
    /s/ Alan L. Rubino   Director
    Alan L. Rubino    
         
    /s/ Heidi M. Hagen   Director
    Heidi M. Hagen    
         
    /s/ Kevin F. McLaughlin   Director
    Kevin F. McLaughlin    
         
    /s/ Paul K. Wotton   Director
    Paul K. Wotton    
         
    /s/ Lisa Wright   Director
    Lisa Wright    

     

     

     

    Get the next $VCEL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VCEL

    DatePrice TargetRatingAnalyst
    8/9/2024$57.00Buy
    Canaccord Genuity
    6/20/2024$55.00Buy
    TD Cowen
    1/25/2024$39.00 → $51.00Hold → Buy
    Truist
    8/8/2023$39.00Neutral → Buy
    BTIG Research
    11/10/2022Buy → Neutral
    BTIG Research
    11/9/2022Buy → Hold
    Truist
    10/14/2022$40.00Overweight
    Stephens
    2/25/2022$40.00 → $45.00Outperform
    SVB Leerink
    More analyst ratings

    $VCEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mclaughlin Kevin F exercised 7,000 shares at a strike of $2.76 and sold $251,440 worth of shares (7,000 units at $35.92) (SEC Form 4)

    4 - Vericel Corp (0000887359) (Issuer)

    8/8/25 4:05:27 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Hopper Jonathan Mark exercised 10,000 shares at a strike of $18.00 and sold $400,900 worth of shares (10,000 units at $40.09) (SEC Form 4)

    4 - Vericel Corp (0000887359) (Issuer)

    6/4/25 4:05:57 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Colangelo Dominick sold $1,178,156 worth of shares (28,125 units at $41.89) and exercised 28,125 shares at a strike of $2.65 (SEC Form 4)

    4 - Vericel Corp (0000887359) (Issuer)

    5/16/25 4:06:11 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VCEL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vericel Reports Second Quarter 2025 Financial Results

    Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased More than 400 Basis Points to 74% Adjusted EBITDA Growth of 112% to $13.4 Million, with Adjusted EBITDA Margin Increase of More than 900 Basis Points to 21% Approximately 600 MACI Arthro Surgeons Trained to Date Received FDA IND Clearance for Phase 3 MACI Ankle Clinical Study Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarte

    7/31/25 8:08:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vericel to Report Second-Quarter 2025 Financial Results on July 31, 2025

    CAMBRIDGE, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its second-quarter 2025 financial results on Thursday, July 31, 2025. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Presentation slides for the conference call will be available on the webcast and on the website. A replay of the webcast will be avail

    7/17/25 8:30:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025

    CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will participate in a fireside chat at the Truist Securities MedTech Conference at 9:20 a.m. ET on Tuesday, June 17 2025. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel Corporation Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a hi

    6/10/25 8:30:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VCEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Vericel with a new price target

    Canaccord Genuity initiated coverage of Vericel with a rating of Buy and set a new price target of $57.00

    8/9/24 8:07:19 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TD Cowen initiated coverage on Vericel with a new price target

    TD Cowen initiated coverage of Vericel with a rating of Buy and set a new price target of $55.00

    6/20/24 7:39:49 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vericel upgraded by Truist with a new price target

    Truist upgraded Vericel from Hold to Buy and set a new price target of $51.00 from $39.00 previously

    1/25/24 7:21:09 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VCEL
    SEC Filings

    View All

    SEC Form 10-Q filed by Vericel Corporation

    10-Q - Vericel Corp (0000887359) (Filer)

    7/31/25 8:50:37 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vericel Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Vericel Corp (0000887359) (Filer)

    7/31/25 8:14:39 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Vericel Corporation

    SCHEDULE 13G/A - Vericel Corp (0000887359) (Subject)

    5/15/25 12:58:39 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VCEL
    Leadership Updates

    Live Leadership Updates

    View All

    Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer

    CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen, who served as Vericel's Head of Human Resources since September 2010. Ms. Mahoney joins Vericel with more than 20 years of experience across the life sciences and medical device sectors, most recently serving as Chief Human Resources Officer at Abiomed, a global medical device company that was acquired by Johnson & Johnson in December 2022. At Abiomed, Ms. Mahoney led all aspects of HR strategy and

    7/22/24 8:30:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    A-Alpha Bio Welcomes Heidi Hagen to Its Board of Directors

    Hagen, Former Chief Technical Officer of Sonoma Biotherapeutics, Joins as A-Alpha's First Independent Board Member SEATTLE, June 27, 2023 /PRNewswire-PRWeb/ -- A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions, announced the appointment of Heidi Hagen to their Board of Directors. Hagen will be A-Alpha Bio's first independent board member. Hagen has been a leader in the Biotechnology industry for 30 years. Over the course of her career, she has built an extensive track record in leading strategy and operations to progress innovative technologies from ideation to commercialization. Having been a core member of pharma companie

    6/27/23 9:00:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kytopen Appoints Paul K. Wotton, Ph.D. to Chair of Board of Directors

    New Independent Board Chair, Dr. Paul K. Wotton, brings 35 years of experience building private and public biopharmaceutical companies with significant business development expertise. Kytopen, an MIT-spin out and biotechnology company leading advancements in novel high-throughput cellular and genome engineering platforms, today announced the appointment of Paul K. Wotton, Ph.D. to Chair the Kytopen Board of Directors. Following the appointment of Dr. Wotton, the Board will comprise of five directors including Ann DeWitt, Adam Wieschhaus, Cullen Buie, and Paulo Garcia. Dr. Paul Wotton received his Ph.D. in Pharmaceutical Sciences from the University of Nottingham and is an experienced CEO,

    1/5/23 9:00:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VCEL
    Financials

    Live finance-specific insights

    View All

    Vericel Reports Second Quarter 2025 Financial Results

    Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased More than 400 Basis Points to 74% Adjusted EBITDA Growth of 112% to $13.4 Million, with Adjusted EBITDA Margin Increase of More than 900 Basis Points to 21% Approximately 600 MACI Arthro Surgeons Trained to Date Received FDA IND Clearance for Phase 3 MACI Ankle Clinical Study Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarte

    7/31/25 8:08:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vericel to Report Second-Quarter 2025 Financial Results on July 31, 2025

    CAMBRIDGE, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its second-quarter 2025 financial results on Thursday, July 31, 2025. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Presentation slides for the conference call will be available on the webcast and on the website. A replay of the webcast will be avail

    7/17/25 8:30:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance

    Record First Quarter MACI Revenue of $46.3 Million and First Quarter Total Revenue of $52.6 Million Approximately 400 MACI Arthro Surgeons Trained to Date, with Year-to-Date Biopsy Growth Over 30% for Trained Surgeons Second Quarter Total Revenue and MACI Revenue Growth Expected to be in the Low- to Mid-20% Range Full-Year 2025 Revenue Guidance Reaffirmed and Profitability Guidance Raised Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business hi

    5/8/25 7:55:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VCEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vericel Corporation

    SC 13G/A - Vericel Corp (0000887359) (Subject)

    11/14/24 1:46:57 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vericel Corporation

    SC 13G/A - Vericel Corp (0000887359) (Subject)

    11/14/24 6:19:59 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vericel Corporation

    SC 13G/A - Vericel Corp (0000887359) (Subject)

    10/18/24 12:21:30 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care